HeartFlow
$1.5Bpaper valuation
// OVERVIEW
HeartFlow spent fifteen years convincing cardiologists that AI could read coronary CT scans better than they could, achieved FDA clearance in 2014, and still operates as a private company valued at $1.5 billion despite being clinically validated by every major cardiology society. The technology works — the question is whether a diagnostic tool that reduces unnecessary catheterizations can build a business model that survives reimbursement warfare with Medicare and commercial insurers who pay $1,500 per scan.
// HQ
Redwood City, United States
// STATUS
PRIVATE
// FOUNDED
2007
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
ai
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
HeartFlow's FFR-CT analysis uses computational fluid dynamics to model blood flow through coronary arteries from standard CT angiography images, generating a non-invasive fractional flow reserve measurement that previously required invasive catheterization. The AI produces patient-specific 3D coronary models and quantifies stenosis severity with 86% sensitivity and 79% specificity validated across multiple clinical trials. Medicare approved reimbursement in 2021 at $1,477 per analysis, making it the first AI diagnostic to achieve Category I CPT code status.
// WOWLS ASSESSMENT
HeartFlow has genuine clinical utility — the ADVANCE registry showed 67% of patients avoided unnecessary catheterizations and the technology is endorsed by the American College of Cardiology. The business model depends entirely on sustained reimbursement at current rates, and CMS has already signaled scrutiny of high-cost imaging diagnostics as part of the 2025 Physician Fee Schedule proposed cuts. The company processes approximately 100,000 analyses annually, generating an estimated $140-160 million in revenue against a $1.5 billion valuation requiring 9-10x growth to justify the multiple. Competitors are emerging — Siemens Healthineers launched a competing AI FFR product in Europe in 2023, and every major medical imaging company now has coronary flow analysis in development. The moat is not the algorithm — it is the ten-year head start on clinical validation and payer relationships, and those advantages compress rapidly once reimbursement codes exist and competitors can cite HeartFlow's own trial data to achieve clearance.
// WHY WOWLS HUNTS THIS
A decade of clinical trials to prove the technology works and three years post-reimbursement approval still private at 9x revenue. The company that eliminates unnecessary procedures is discovering that eliminating revenue is not a business model insurers reward generously.
// VALUATION NOTE
Revenue estimated at $140-160M based on approximately 100,000 annual analyses at Medicare reimbursement rate of $1,477 per scan. Company has not disclosed financial metrics publicly.
VERDICT: ARMED — The company built a $1.5 billion valuation on a technology that reduces healthcare costs, and now faces the predictable consequence that payers want to pay less for it
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track HeartFlow.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on HeartFlow?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN